Equities

Niagen Bioscience Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Niagen Bioscience Inc

Actions
  • Price (EUR)4.44
  • Today's Change-0.36 / -7.50%
  • Shares traded500.00
  • 1 Year change-17.78%
  • Beta2.1169
Data delayed at least 15 minutes, as of Feb 06 2026 07:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Niagen Bioscience, Inc. specializes in nicotinamide adenine dinucleotide (NAD+) science and healthy-aging research. At the center of its clinically proven product portfolio is Niagen (patented nicotinamide riboside or NR). Niagen powers its consumer supplement, Tru Niagen, a NAD+ boosting oral supplement in the United States, and Niagen Plus, featuring pharmaceutical-grade intravenous and injectable Niagen products. Its segments include Consumer Products, Ingredients, and Analytical Reference Standards and Services. Consumer Products segment provides finished dietary supplement products containing its proprietary ingredients directly to consumers and distributors, as well as NAD+ test kits exclusively to healthcare practitioners. Ingredients segment develops and commercializes proprietary-based ingredient technologies. Analytical Reference Standards and Services segment is focused on natural product fine chemicals, known as phytochemicals, and related research and development services.

  • Revenue in USD (TTM)124.71m
  • Net income in USD20.43m
  • Incorporated2008
  • Employees104.00
  • Location
    Niagen Bioscience Inc10900 Wilshire Blvd Suite 600LOS ANGELES 90024United StatesUSA
  • Phone+1 (310) 388-6706
  • Fax+1 (302) 421-5753
  • Websitehttps://www.niagenbioscience.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.